| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5824935 | Clinical Therapeutics | 2015 | 5 Pages |
Abstract
Significant improvements in headache frequency and intensity were observed. Chronic migraine is not an indication approved by the US Food and Drug Administration for incobotulinumtoxinA; however, the drug's effectiveness was documented in this small patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Rashid PharmD, BCPS, Jane BS, Ashley Blake PharmD, Stephanie MD,